Trastuzumab, the pioneering monoclonal antibody, was the first FDA-approved targeted therapy in 1998 for HER2+ BC, followed by lapatinib, pertuzumab, and trastuzumab emtansine. The gene discussed is ERBB2; the disease is breast cancer.